COMMUNIQUÉS West-GlobeNewswire

JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
20/04/2026
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary [...]
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
20/04/2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
20/04/2026
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
MISE À JOUR -- BVI annonce l’obtention du marquage CE au titre du Règlement européen sur les dispositifs médicaux pour Virtuoso®, une toute nouvelle plateforme chirurgicale à double fonction
20/04/2026
Le marquage CE au titre du Règlement européen sur les dispositifs médicaux (MDR de l’UE) a été obtenu pour Virtuoso®, la première plateforme de phaco-vitrectomie à double fonction de BVI, conçue pour offrir un contrôle [...]
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
20/04/2026
First‑in‑class DARKFOX‑targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, enabling precise redirection of T [...]
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
21/04/2026
Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) -- Provectus [...]
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
21/04/2026
FDA 授予 Daretabart (hu1418K322A) 快速通道认定资格，以解决高危神经母细胞瘤领域存在的重大未满足医疗需求，允许该药物进入加速评审和滚动审评流程 FDA 通过新药临床研究 (IND) 申请后，即可在高危神经母细胞瘤复发及难治性患者中启动 SHINE II/III 期临床试验 Daretabart (hu1418K322A) 第一个商业化规模 GMP 生产批次已顺利完成项目基于 II 期的积极数据， [...]
Moonbird Claims Evaluated: Guided Breathing Therapy Device for Meditation-Like Calming Benefits for Relaxation & Sleep Support
21/04/2026
A 2026 informational overview of Moonbird's tactile breathing coach technology, EEG brain scan research references, real-time HRV biofeedback, pricing structure, and what prospective buyers should know before ordering [...]
Herz P1 Smart BPM Under Investigation: Clinical-Grade Blood Pressure Monitoring for Valuable At-Home Health Tracking Support
20/04/2026
A 2026 informational overview of Herz P1 Smart BPM FDA 510K clearance, wrist blood pressure monitor accuracy considerations, irregular heartbeat detection features, at-home cardiovascular tracking awareness, and key [...]
IBA – ACQUISITION OF OWN SHARES
20/04/2026
Louvain-la-Neuve, Belgium, April 20 th , 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
IBA – ACQUISITION D’ACTIONS PROPRES
20/04/2026
Louvain-la-Neuve, Belgique, 20 avril 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment [...]
FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
20/04/2026
Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as [...]
ViriFlow Claims Evaluated: The Prostate-Supporting Formula for Men That Actually Works in Viri Flow Drops Reviewed
20/04/2026
A 2026 informational overview of ViriFlow's hard water mineral theory, saw palmetto and iodine-rich seaweed blend research, proprietary blend dosing transparency, liquid dropper format considerations, prostate [...]
AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA
20/04/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV DÉMONTRANT DES BÉNÉFICES SUBSTANTIELS EN TERMES DE SURVIE ET DE QUALITÉ DE VIE PRÉSERVÉE AVEC LE MASITINIB CHEZ LES PATIENTS ATTEINTS DE [...]
Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting
20/04/2026
New York, NY, April 20, 2026 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new LX- [...]
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives in Canada and Reduce Health System Costs Across G7 Countries
20/04/2026
42,000 Canadians are hospitalized with bloodstream infections each year. New findings show fast diagnostics could prevent 2,400 of those patients annually from progressing to sepsis and save $42M for the Canadian [...]
GENFIT : Publication du rapport de performance extra-financière 2026 (exercice 2025)
20/04/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 20 avril 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
20/04/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]

Pages